Clinical study for PD-1 antibody SHR-1210 combined with apatinib in the first line treatment of advanced triple negative breast cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900028637

Enrollment

Unknown

Registered

2019-12-29

Start date

2020-01-01

Completion date

Unknown

Last updated

2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Case series:apatinib+SHR-1210

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 ~ 75 years old, male and female; 2. Advanced triple negative breast cancer without primary treatment confirmed by histology or cytology; 3. No systemic treatment was received after the diagnosis of the transfer; 4. There are measurable lesions that meet the iRECIST critiea; 5. Normal organ function.

Exclusion criteria

Exclusion criteria: 1. Patients have not been treated after diagnosis of metastasis; 2. Symptomatic brain metastases; 3. allergies to apatinib mesylate, SHR-1210 or any ingredient; 4. blood vessel invasion; 5. Autoimmune disease; 6. Patients at risk of gastrointestinal bleeding.

Design outcomes

Primary

Measure	Time frame
PFS;	—

Secondary

Measure	Time frame
OS;DCR;ORR;QOL;	—

Countries

China

Contacts

Public ContactWEIHONG ZHAO

PLA General Hospital

zhaowh0818@163.com+86 15910853879

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026